Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board

Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board

The Max Foundation is thrilled to welcome longtime advisor, Dr. Jerald Radich of the Fred Hutchinson Cancer Research Institute into the Executive Board.  Dr. Radich has been a guiding star in our innovative work for many years helping people face cancer with dignity and hope, especially in the area of improving access to critical diagnostics in low- and middle-income countries.

Last year, The Max Foundation created a formal partnership with Fred Hutch and the Radich Lab called Spot On CML in order to increase testing for chronic myeloid leukemia (CML) patients.  The Spot On CML partnership aims to test 365 patients in a year and has already helped patients in Mongolia, Nepal, Tajikistan, Timor Leste, and beyond.

Dr. Radich has an accomplished background.  He is a medical oncologist who specializes in the molecular genetics of leukemia. A world-recognized expert in chronic myeloid leukemia (CML), he serves on the CML Guidelines Panels for the National Comprehensive Cancer Network and European LeukemiaNet, which synthesize the best available evidence, including findings from state-of-the-art molecular monitoring, to support optimal decision-making in the medical management of CML patients.  For many years, Dr. Radich has been involved with The Max Foundation and the International CML Foundation (iCMLf), performing diagnostic and monitoring tests for CML patients in developing countries.

The Radich laboratory was one of the first to document that monitoring levels of the abnormal, CML-promoting “BCR-ABL” fusion protein can be used to detect “minimal residual disease” and predict relapse before CML cells can be detected by previously standard tests. Dr. Radich’s Lab was recognized in a New York Times article for their breakthrough work that continues to benefit patients today.

We are grateful for Dr. Radich’s ongoing support and thank him, in advance, for his continued guidance on behalf of people facing cancer worldwide.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation to Launch Treatment Access for Advanced Breast Cancer in Nine Countries Across Africa, Latin America, and South Asia in Q3 2023

    The Max Foundation to Launch Treatment Access for Advanced Breast Cancer in Nine Countries Across Africa, Latin America, and South Asia in Q3 2023

    The Max Foundation to launch its Max Access Solutions program for patients with HR+/HER2- advanced breast cancer in collaboration with leading oncologists in low- and middle-income countries (LMICs) and the ABC Global Alliance, the American Society for Clinical Pathology, Cepheid, and Novartis AG First patients to receive treatment in Bahamas, Benin, Bhutan, Haiti, Jamaica, Mozambique,….

  • The Max Foundation Creates Subsidiary Organization, MaxAid, to Further Mission

    Now in its 20th year, The Max Foundation is undergoing exciting strategic changes aimed at strengthening organizational efforts to improve global access to cancer treatment, care and support. To that end, we announce the launch of MaxAid, a subsidiary organization set up by The Max Foundation to further its mission. MaxAid is a Washington nonprofit corporation with its own IRS determination letter of 501(c)(3) public charity status.

  • Welcoming Dr. Michael J. Wagner, MD, to The Max Foundation’s Medical Advisory Board

    Welcoming Dr. Michael J. Wagner, MD, to The Max Foundation’s Medical Advisory Board

    The Max Foundation is thrilled to welcome Dr. Michael J. Wagner to our Gastrointestinal Stromal Tumor (GIST) Medical Advisory Board. Since we met Dr. Wagner in early 2020 at a GIST patient meeting in Seattle, he has provided our program with invaluable training and support. “Dr. Wagner has gone above and beyond in advising our….